VRB-101
Oral ecnoglutide · Ecnoglutide oral · XW004 · Verdiva Bio
A once-weekly oral formulation of ecnoglutide, a GLP-1 peptide analogue.
Results availability
No numerical study results are currently summarized for this profile. The development stage and linked studies are listed below.
Mechanism at a glance
Obesity stage by formulation
Latest: EVOLVE-2 Phase 2b is listed as completed, with topline results expected by year-end 2026. A separate Phase 2 weight-maintenance study was terminated after eight participants; the sponsor described a business decision not based on safety findings.
Next: EVOLVE-2 topline and the next development decision.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 2 studies2 records
EVOLVE-2 · NCT07281937
Weight managementA 20-week study of once-weekly oral VRB-101 in adults with obesity or overweight plus weight-related comorbidities; the registry lists the study as completed.
VRB-101-202 · weight maintenance
Weight maintenanceSeparate from EVOLVE-2. Terminated after eight participants. The sponsor stated this was a business decision and not based on safety findings. This study termination does not establish termination of the full program.
